After years of work, MAPS/Lykos was finally able to present MDMA to the FDA as a possible tool in the fight against PTSD, only to be denied in devastating fashion. Just why did the FDA reject MDMA-assisted therapy for PTSD? In this episode, Joe interviews Ingmar Gorman, Ph.D.: clinical psychologist and co-founder and CEO of […]

The post Why Did the FDA Reject MDMA-Assisted Therapy for PTSD? appeared first on Psychedelics Today.

Previous articleCould Psychedelics Transform How Doctors Treat Chronic Pain?
Next articlePα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute